$123.26 Million in Sales Expected for Collegium Pharmaceutical, Inc. (NASDAQ:COLL) This Quarter

Wall Street brokerages expect Collegium Pharmaceutical, Inc. (NASDAQ:COLLGet Rating) to report $123.26 million in sales for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Collegium Pharmaceutical’s earnings, with the highest sales estimate coming in at $126.10 million and the lowest estimate coming in at $120.66 million. Collegium Pharmaceutical posted sales of $82.94 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 48.6%. The company is scheduled to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Collegium Pharmaceutical will report full-year sales of $457.68 million for the current fiscal year, with estimates ranging from $451.37 million to $464.10 million. For the next financial year, analysts anticipate that the firm will report sales of $570.56 million, with estimates ranging from $554.82 million to $597.44 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLLGet Rating) last posted its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported $0.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.46). The firm had revenue of $83.80 million for the quarter, compared to the consensus estimate of $78.67 million. Collegium Pharmaceutical had a return on equity of 3.26% and a net margin of 15.68%. Collegium Pharmaceutical’s quarterly revenue was down 4.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.41 EPS.

A number of equities analysts have weighed in on COLL shares. Needham & Company LLC boosted their price objective on Collegium Pharmaceutical from $34.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday, April 6th. Cantor Fitzgerald raised Collegium Pharmaceutical from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $18.00 to $26.00 in a research report on Tuesday, February 15th. Zacks Investment Research cut Collegium Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Tuesday, April 26th. HC Wainwright increased their price objective on Collegium Pharmaceutical from $26.00 to $29.00 and gave the stock a “buy” rating in a research report on Tuesday, February 15th. Finally, TheStreet downgraded Collegium Pharmaceutical from a “b-” rating to a “c+” rating in a research note on Monday, April 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Collegium Pharmaceutical presently has an average rating of “Buy” and a consensus target price of $31.00.

Several institutional investors have recently bought and sold shares of COLL. Principal Financial Group Inc. raised its position in Collegium Pharmaceutical by 23.5% in the fourth quarter. Principal Financial Group Inc. now owns 1,305,743 shares of the specialty pharmaceutical company’s stock worth $24,391,000 after purchasing an additional 248,132 shares in the last quarter. Emerald Advisers LLC raised its holdings in Collegium Pharmaceutical by 39.2% in the first quarter. Emerald Advisers LLC now owns 800,118 shares of the specialty pharmaceutical company’s stock worth $16,290,000 after purchasing an additional 225,281 shares during the period. LSV Asset Management raised its holdings in Collegium Pharmaceutical by 146.3% in the fourth quarter. LSV Asset Management now owns 361,800 shares of the specialty pharmaceutical company’s stock worth $6,758,000 after purchasing an additional 214,900 shares during the period. Rubric Capital Management LP raised its holdings in shares of Collegium Pharmaceutical by 7.7% during the third quarter. Rubric Capital Management LP now owns 2,606,500 shares of the specialty pharmaceutical company’s stock worth $51,452,000 after acquiring an additional 186,286 shares during the period. Finally, State Street Corp raised its holdings in shares of Collegium Pharmaceutical by 14.4% during the first quarter. State Street Corp now owns 1,308,167 shares of the specialty pharmaceutical company’s stock worth $26,634,000 after acquiring an additional 165,144 shares during the period.

Shares of COLL stock opened at $15.65 on Tuesday. The stock has a 50 day moving average of $17.80 and a 200 day moving average of $18.46. The company has a current ratio of 0.97, a quick ratio of 0.76 and a debt-to-equity ratio of 3.41. The stock has a market cap of $530.89 million, a P/E ratio of 17.58, a P/E/G ratio of 0.16 and a beta of 1.07. Collegium Pharmaceutical has a twelve month low of $14.04 and a twelve month high of $25.66.

Collegium Pharmaceutical Company Profile (Get Rating)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.

Featured Stories

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.